Vol. 14. Núm. 54.
Páginas 3259-3272 (Mayo 2026)

Actualización
Infección nosocomial en el área médica

Nosocomial infection in the medical setting

M.D. Corbacho-LoarteabcM. Suárez-RoblesabcR. Navarro-SolerabcM. Rosas Cancio-SuárezabcC.M. CanoabcJ. Díaz-ÁlvarezabcD. Gayoso-CanteroabcA.G. García-Ruiz de MoralesabcS. Morenoabc
Doi : https://10.1016/j.med.2026.04.019
Opciones
Resumen

Las infecciones nosocomiales son complicaciones comunes en pacientes hospitalizados, afectando su salud y generando altos costes. Esta actualización revisa las infecciones asociadas a dispositivos médicos y las situaciones clínicas específicas. Las infecciones por catéter vascular son frecuentes y se dividen en formas localizadas y sistémicas. Los principales patógenos son Staphylococcus epidermidis y S. aureus. El tratamiento generalmente requiere la retirada del catéter y el uso de antibióticos empíricos. Los catéteres de hemodiálisis también son fuentes de infección, siendo S. aureus uno de los principales causantes. Se diagnostican con hemocultivos y suelen requerir antibioterapia y retirada del catéter.

La neumonía hospitalaria es la segunda infección más común y puede ser fatal. Se diagnostica por la clínica y los cultivos. Además, en pacientes con tumores, la neutropenia febril debe ser tratada con antibioterapia. La peritonitis bacteriana espontánea se maneja con cefalosporinas y prevención con antibióticos. En conclusión, podemos decir que el reconocimiento precoz, el inicio rápido del tratamiento antimicrobiano y la implementación de estrategias preventivas resultan clave para mejorar el pronóstico de estas infecciones nosocomiales.

Palabras clave
Catéteres
Bacteriemia
Neumonía
Peritonitis
Abstract

Nosocomial infections are common complications in hospitalized patients, affecting their health and generating high costs. This update reviews infections associated with medical devices and specific clinical situations. Vascular catheter-related infections are common. They are divided into localized and systemic forms. The main pathogens are Staphylococcus epidermidis and S. aureus. Treatment generally requires catheter removal and the use of empirical antibiotics. Hemodialysis catheters are also sources of infection, with S. aureus being one of the main causative agents. They are diagnosed via blood cultures and typically require antibiotic therapy and catheter removal.

Hospital-acquired pneumonia is the second most common infection and can be fatal. It is diagnosed based on symptoms and cultures. Additionally, in patients with tumors, febrile neutropenia should be treated with antibiotic therapy. Spontaneous bacterial peritonitis is managed with cephalosporins and prevented with antibiotics. In conclusion, it can be stated that early recognition, rapid initiation of antimicrobial treatment, and the implementation of preventive strategies are key to improving the prognosis of these nosocomial infections.

Keywords
Catheters
Bacteremia
Pneumonia
Peritonitis

Identifíquese

¿Aún no es suscriptor de la revista?

Comprar el acceso al artículo

Comprando el artículo el pdf del mismo podrá ser descargado

Teléfono para incidencias

De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h

Llamadas desde España 932 415 960
Llamadas desde fuera de España +34 932 415 960
Bibliografía
[1]
L.A. Mermel
202605140410316838
202605140410316839
, M. Allon, E. Bouza, D.E. Craven, P. Flynn, N.P. O’Grady, et al.
Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.
Clin Infect Dis., (2009), 49 pp. 1-45
[2]
F. Chaves
2026051404103168310
2026051404103168311
, J. Garnacho-Montero, J.L. Del Pozo, E. Bouza, J.A. Capdevila, M. de Cueto, et al.
Diagnosis and treatment of catheter-related bloodstream infection: clinical guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC).
Med Intensiva (Engl Ed)., (2018), 42 pp. 5-36
[3]
M. Nucci
2026051404103168312
, E. Anaissie.
Should vascular catheters be removed from all patients with candidemia? An evidence-based review.
Clin Infect Dis., (2002), 34 pp. 591-599
[4]
N. Fernandez-Hidalgo
2026051404103168313
2026051404103168314
, B. Almirante, R. Calleja, I. Ruiz, A.M. Planes, D. Rodriguez, et al.
Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study.
J Antimicrob Chemother., (2006), 57 pp. 1172-1180
[5]
N.P. O’Grady
2026051404103168315
2026051404103168316
, M. Alexander, L.A. Burns, E.P. Dellinger, J. Garland, S.O. Heard, et al.
Guidelines for the prevention of intravascular catheter-related infections.
N Engl J Med., (2011), 365 pp. 2327-2339
[6]
L.M. Miller
2026051404103168317
, E. Clark, C. Dipchand, S. Hiremath, J. Kappel, M. Kiaii, et al.
Hemodialysis tunneled catheter-related infections.
Can J Kidney Health Dis., (2016), 27
[7]
L. Skov Dalgaard, M. Nørgaard, B. Jespersen, S. Jensen-Fangel, L.J. Østergaard, H.C. Schønheyder, et al.
Risk and prognosis of bloodstream infections among patients on chronic hemodialysis: a population-based cohort study.
PLoS One., (2015), 10 pp. e0124547
[8]
K.M. Chow
2026051404103168318
2026051404103168319
, P.K.T. Li, Y. Cho, A. Abu-Alfa, S. Bavanandan, E.A. Brown, et al.
ISPD catheter-related infection recommendations: 2023 update.
Perit Dial Int., (2023), 43 pp. 201-219
[9]
C. Muthukuda, V. Suriyakumara, T. Samarathunga, L. Liyanage, A. Marasinghe.
Non-tunneled haemodialysis catheter-related bloodstream infections and associated factors among first time haemodialysis patients: a prospective study from a tertiary care hospital in Sri Lanka.
BMC Nephrol., (2024), 25 pp. 280
[10]
M. Allon
2026051404103168320
.
Dialysis catheter-related bacteremia: treatment and prophylaxis.
Am J Kidney Dis., (2004), 44 pp. 779-791
[11]
B. Piraino
2026051404103168321
, J. Bernardini, E. Brown, A. Figueiredo, D.W. Johnson, W.C. Lye, et al.
ISPD position statement on reducing the risks of peritoneal dialysis-related infections.
Perit Dial Int., (2011), 31 pp. 614-630
[12]
P.K.-T. Li
2026051404103168322
2026051404103168323
, C.C. Szeto, B. Piraino, J. de Arteaga, S. Fan, A.E. Figueiredo, et al.
ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment.
Perit Dial Int., (2016), 36 pp. 481-508
[13]
Mupirocin Study Group.
Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis.
J Am Soc Nephrol., (1996), 7 pp. 2403-2408
[14]
Y. Obata
2026051404103168324
, M. Murashima, N. Toda, S. Yamamoto, Y. Tsujimoto, Y. Tsujimoto, et al.
Topical application of mupirocin to exit sites in patients on peritoneal dialysis: a systematic review and meta-analysis of randomized controlled trials.
Ren Replace Ther., (2020), 6 pp. 12
[15]
D. Koulenti, E. Tsigou, J. Rello.
Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study.
Eur J Clin Microbiol Infect Dis., (2017), 36 pp. 1999-2006
[16]
L. Papazian
2026051404103168325
, M. Klompas, C.E. Luyt.
Ventilator-associated pneumonia in adults: a narrative review.
Intensive Care Med., (2020), 46 pp. 888-906
[17]
A.C. Kalil
2026051404103168326
2026051404103168327
, M.L. Metersky, M. Klompas, J. Muscedere, D.A. Sweeney, L.B. Palmer, et al.
Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society.
Clin Infect Dis., (2016), 63 pp. e61-e111
[18]
A. Torres
2026051404103168328
2026051404103168329
, M.S. Niederman, J. Chastre, S. Ewig, P. Fernandez-Vandellos, H. Hanberger, et al.
International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia.
Eur Respir J., (2017), 50 pp. 1700582
[19]
M. Bassetti, E. Righi, A. Vena, E. Graziano, A. Russo, M. Peghin.
Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug-resistant/extensively drug-resistant/pandrug-resistant bacteria.
Curr Opin Crit Care., (2018), 24 pp. 385-393
[20]
J. Klastersky, M. Paesmans, E.B. Rubenstein, M. Boyer, L. Elting, R. Feld, et al.
The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients.
J Clin Oncol., (2000), 18 pp. 3038-3051
[21]
Sociedad
2026051404103168330
Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC). Proyecto Neumonía Zero. Madrid: SEMICYUC; 2011. https://semicyuc.org/proyectos/neumonia-zero.
[22]
A. Carmona-Bayonas
2026051404103168331
, P. Jiménez-Fonseca, J.A. Virizuela, M. Antonio, C. Font, M. Biosca, et al.
Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia (CISNE).
Ann Oncol., (2015), 26 pp. 386-391
[23]
A.G. Freifeld, E.J. Bow, K.A. Sepkowitz, M.J. Boeckh, J.I. Ito, C.A. Mullen, et al.
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by IDSA.
Clin Infect Dis., (2011), 52 pp. e56-e93
[24]
J. Klastersky, J. de Naurois, K. Rolston, B. Rapoport, G. Maschmeyer, M. Aapro, et al.
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.
Ann Oncol., (2016), 27Suppl5 pp. v111-v118
[25]
European
2026051404103168332
2026051404103168333
Association for the Study of the Liver (EASL).
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.
J Hepatol., (2010), 53 pp. 397-417
[26]
A. Koulaouzidis, S. Bhat, A.A. Saeed.
Spontaneous bacterial peritonitis.
World J Gastroenterol., (2009), 15 pp. 1042-1049
[27]
L.T. Evans, W.R. Kim, J.J. Poterucha, P.S. Kamath.
Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites.
Hepatology., (2003), 37 pp. 897-901
[28]
H.O. Conn.
Spontaneous peritonitis and bacteremia in Laennec's cirrhosis caused by enteric organisms.
Ann Intern Med., (1964), 60 pp. 568-580
[29]
S.W. Biggins
2026051404103168334
2026051404103168335
, P. Angeli, G. Garcia-Tsao, P. Ginès, S.C. Ling, M.K. Nadim, et al.
Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
Hepatology., (2021), 74 pp. 1014-1048
[30]
G. García-Tsao.
Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis.
Gastroenterology., (2001), 120 pp. 726-748
[31]
P. Sort, M. Navasa, V. Arroyo, X. Aldeguer, R. Planas, L. Ruiz-del-Arbol, et al.
Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.
N Engl J Med., (1999), 341 pp. 403-409
[32]
B.A. Runyon, J.C. Hoefs.
Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis.
Hepatology., (1984), 4 pp. 1209-1211
[33]
B.A. Runyon.
Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis.
Hepatology., (1990), 12 pp. 710-715